EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 371 filers reported holding EXELIXIS INC in Q3 2020. The put-call ratio across all filers is 2.74 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,583,708 | -10.4% | 70,481 | -5.4% | 0.06% | -14.5% |
Q1 2024 | $1,768,407 | -1.0% | 74,522 | +0.0% | 0.07% | -10.4% |
Q4 2023 | $1,787,135 | +9.5% | 74,495 | -0.3% | 0.08% | -14.4% |
Q3 2023 | $1,631,955 | -1.9% | 74,689 | -14.2% | 0.09% | +1.1% |
Q2 2023 | $1,663,220 | +0.5% | 87,034 | +2.1% | 0.09% | -12.7% |
Q1 2023 | $1,654,741 | +121.4% | 85,252 | +82.9% | 0.10% | +108.2% |
Q4 2022 | $747,448 | +3.2% | 46,599 | +0.9% | 0.05% | -5.8% |
Q3 2022 | $724,000 | -28.4% | 46,192 | -4.9% | 0.05% | -18.8% |
Q2 2022 | $1,011,000 | -18.5% | 48,577 | -11.2% | 0.06% | +23.1% |
Q1 2022 | $1,241,000 | +18.1% | 54,730 | -4.8% | 0.05% | +52.9% |
Q4 2021 | $1,051,000 | -25.0% | 57,492 | -13.3% | 0.03% | -27.7% |
Q3 2021 | $1,401,000 | +9.7% | 66,278 | -5.4% | 0.05% | +9.3% |
Q2 2021 | $1,277,000 | -21.2% | 70,092 | -2.3% | 0.04% | -30.6% |
Q1 2021 | $1,621,000 | -6.8% | 71,770 | -17.2% | 0.06% | -18.4% |
Q4 2020 | $1,739,000 | -11.1% | 86,632 | +8.3% | 0.08% | -24.8% |
Q3 2020 | $1,957,000 | +2.1% | 80,026 | -0.9% | 0.10% | -5.6% |
Q2 2020 | $1,917,000 | +64.7% | 80,749 | +19.5% | 0.11% | +23.0% |
Q1 2020 | $1,164,000 | -32.5% | 67,596 | -30.9% | 0.09% | +16.0% |
Q4 2019 | $1,725,000 | +7.9% | 97,886 | +8.3% | 0.08% | -7.4% |
Q3 2019 | $1,598,000 | -24.2% | 90,376 | -8.4% | 0.08% | -19.0% |
Q2 2019 | $2,108,000 | -19.4% | 98,638 | -10.2% | 0.10% | -20.6% |
Q1 2019 | $2,615,000 | +33.3% | 109,865 | +10.1% | 0.13% | +4.1% |
Q4 2018 | $1,962,000 | -17.6% | 99,750 | -25.8% | 0.12% | +34.4% |
Q3 2018 | $2,381,000 | -10.4% | 134,383 | +8.8% | 0.09% | -15.1% |
Q2 2018 | $2,657,000 | +28.7% | 123,474 | +32.5% | 0.11% | +29.3% |
Q1 2018 | $2,065,000 | -34.1% | 93,214 | -9.6% | 0.08% | -32.2% |
Q4 2017 | $3,133,000 | +11.9% | 103,062 | -10.9% | 0.12% | +3.4% |
Q3 2017 | $2,801,000 | +4729.3% | 115,619 | +572.0% | 0.12% | +3800.0% |
Q2 2014 | $58,000 | -6.5% | 17,205 | -1.1% | 0.00% | 0.0% |
Q1 2014 | $62,000 | -4.6% | 17,400 | +64.4% | 0.00% | 0.0% |
Q4 2013 | $65,000 | – | 10,585 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |